In vitro activity of BMY-28100, a new oral cephalosporin.
The activity of BMY-28100, a new orally administered cephalosporin, was compared with those of cephalexin and cefaclor. BMY-28100 was the most active drug against Staphylococcus aureus (MIC for 90% of strains tested [MIC90], 1.0 microgram/ml), streptococci (MIC90S, less than or equal to 0.125 microgram/ml), and Klebsiella pneumoniae (MIC90, 2 micrograms/ml). The drug was active against Haemophilus influenzae and gonococci but not against other organisms generally resistant to cephem antibiotics.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D001426:Bacterial Proteins / Q000378:metabolism; D002433:Cefaclor / Q000494:pharmacology; D002506:Cephalexin / Q000494:pharmacology; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism; D000097670:Cefprozil
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002433:Cefaclor; D002506:Cephalexin; D002511:Cephalosporins; D001618:beta-Lactamases; D000097670:Cefprozil